Tenofovir
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Tenofovir
- Molecular weight
- 305.23
- Structure (SMILES)
- C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O
- [[(R)-2-(6-Amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonic acid, monohydrate
- gs 1278
- GS-1278
- pmp a
- PMP-A
- pmpa
- PMPA
- r 2 6 amino 9h purin 9 yl 1 methylethoxy methyl phosphonic acid monohydrate
- tenofovir
- Tenofovir
- TENOFOVIR [MART.]
- TENOFOVIR [USAN]
- TENOFOVIR [USP-RS]
- TENOFOVIR [VANDF]
- tenofovir hydrate
- Tenofovir hydrate
- tenofovir mart
- tenofovir monohydrate
- Tenofovir monohydrate
- tenofovir tdf
- tenofovir usan
- tenofovir usp rs
- tenofovir vandf
- tenofovir(TDF)
- ChEMBL ID
- CHEMBL3989702
- InChIKey
- PINIEAOMWQJGBW-FYZOBXCZSA-N
- PubChem compound IDs
- 21146529
- RxNorm IDs (RxCUI)
- 117466
- FDA ingredient codes (UNII)
- 99YXE507IL
- 147127-20-6
- 206184-49-8
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Pharmacology name
- tenofovir
- Type
- Synthetic organic
- Drug name stem
- -vir
- Approval recorded by Guide to Pharmacology
- Yes
- Mechanism
- DNA polymerase/reverse transcriptase inhibitor
- Action type
- Inhibitor
- Target
- DNA polymerase/reverse transcriptase
- Mechanism
- Human immunodeficiency virus type 1 reverse transcriptase inhibitor
- Action type
- Inhibitor
- Target
- Human immunodeficiency virus type 1 reverse transcriptase
- Condition identifier
- EFO_0000180
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000764
- Condition identifier
- EFO_0004197
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004239
- Highest recorded phase
- 3
- Condition identifier
- EFO_0803536
- Highest recorded phase
- 2
- Condition identifier
- EFO_1001248
- Highest recorded phase
- 1
- Condition identifier
- HP_0000093
- Condition identifier
- HP_0001395
- Condition identifier
- HP_0003287
- Condition identifier
- HP_0100578
- Condition identifier
- MONDO_0002691
- Condition identifier
- MONDO_0005109
- Condition identifier
- MONDO_0005109
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005111
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005231
- Condition identifier
- MONDO_0005249
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005301
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005344
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005366
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006052
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0007256
- Condition identifier
- MONDO_0013209
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0016318
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0016537
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0018076
- Highest recorded phase
- 3
And 7 more, listed on the interactive page.
- Event
- abortion spontaneous
- Reports
- 615
- Reporting signal score
- 818.58
- Event
- acute hiv infection
- Reports
- 78
- Reporting signal score
- 334.45
- Event
- birth mark
- Reports
- 24
- Reporting signal score
- 115.49
- Event
- blood creatinine increased
- Reports
- 547
- Reporting signal score
- 503.945
- Event
- blood hiv rna increased
- Reports
- 187
- Reporting signal score
- 626.502
- Event
- blood phosphorus decreased
- Reports
- 125
- Reporting signal score
- 267.99
- Event
- congenital umbilical hernia
- Reports
- 29
- Reporting signal score
- 131.014
- Event
- csf hiv escape syndrome
- Reports
- 78
- Reporting signal score
- 341.694
- Event
- drug resistance
- Reports
- 841
- Reporting signal score
- 1,763.75
- Event
- fanconi syndrome
- Reports
- 199
- Reporting signal score
- 649.568
- Event
- fanconi syndrome acquired
- Reports
- 341
- Reporting signal score
- 1,254.36
- Event
- genotype drug resistance test positive
- Reports
- 149
- Reporting signal score
- 436.13
- Event
- glycosuria
- Reports
- 121
- Reporting signal score
- 361.019
- Event
- hepatitis b
- Reports
- 172
- Reporting signal score
- 333.283
- Event
- hepatitis b dna increased
- Reports
- 81
- Reporting signal score
- 248.204
- Event
- hypophosphataemia
- Reports
- 247
- Reporting signal score
- 508.995
- Event
- immune reconstitution inflammatory syndrome
- Reports
- 416
- Reporting signal score
- 1,117.88
- Event
- immune reconstitution syndrome
- Reports
- 113
- Reporting signal score
- 324.746
- Event
- lipodystrophy acquired
- Reports
- 260
- Reporting signal score
- 828.964
- Event
- mitochondrial toxicity
- Reports
- 154
- Reporting signal score
- 572.403
- Event
- nephropathy toxic
- Reports
- 296
- Reporting signal score
- 527.83
- Event
- osteomalacia
- Reports
- 114
- Reporting signal score
- 317.683
- Event
- osteoporosis
- Reports
- 564
- Reporting signal score
- 1,136.85
- Event
- pathogen resistance
- Reports
- 524
- Reporting signal score
- 1,381.13
- Event
- portal hypertension
- Reports
- 29
- Reporting signal score
- 76.6502
And 14 more, listed on the interactive page.
- Hydrogen bond acceptors
- 7
- Hydrogen bond donors
- 3
- Polar surface area
- 136.38
- Calculated partition coefficient (ALogP)
- -0.05
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 20
- Molecular formula
- C9H16N5O5P
- Monoisotopic mass
- 305.08890563
- Natural product
- No
Related records
Trials (207)
- A Drug-Drug Interaction Study Between ATI-2173 and Tenofovir Disoproxil Fumarate in Healthy Subjects
- A Feasibility Study to Assess Tenofovir and Maraviroc Protection Against HIV-1 in Cervical and Vaginal Explants
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection
- A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection
- A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D
- A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy
- A Phase I Trial to Assess the Safety of Tenofovir Gel and Film Formulations: FAME 04
- A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection
- A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine
- A Single-arm Study Evaluating the Efficacy and Safety of Telbivudine With or Without add-on Tenofovir in Adults With HBeAg-positive Chronic Hepatitis B (CHB)
- A Study Evaluating the Safety, Pharmacokinetics, and Antiviral Efficacy of SB 9200 in Subjects Infected With Chronic HBV
- A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)
- A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or Both
- A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
- A Study of PMPA in HIV-Infected Patients
- A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection
- A Study to Compare Efficacy and Safety of Tenofovir Used Alone or in Combination With Pegylated Interferon Alpha-2b in Participants With Chronic Hepatitis B and Elevated Alanine Aminotransferase (MK-4031-384)
- A Study to Compare Three Different Formulations of Tenofovir 1% Gel When Administered Rectally
- A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy
- A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis
In development for (13)
- Aicardi-Goutieres syndrome Phase 1
- Chronic hepatitis B virus infection Phase 3
- COVID-19 Phase 2
- Diffuse large B-cell lymphoma Phase 2
- Epstein-Barr virus infection Phase 1
- Hepatitis B virus infection Phase 3
- Lymphoproliferative syndrome Phase 1
- Metabolic dysfunction-associated steatotic liver disease Phase 1
- Multiple sclerosis Phase 2
- Pneumonia Phase 2
- Progressive multifocal leukoencephalopathy Phase 2
- Pulmonary tuberculosis Phase 2
- Tuberculosis Phase 3
Other linked conditions (5)
- Hepatitis C virus infection
- Hepatocellular carcinoma
- HIV infectious disease
- Liver cancer
- Liver failure